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Abstract
Background
Snakebite poisoning is a significant medical problem in agricultural societies in Sub Saha-
ran Africa. Antivenom (AV) is the standard treatment, and we assessed the cost-effective-
ness of making it available in 16 countries in West Africa.
Methods
We determined the cost-effectiveness of AV based on a decision-tree model from a public
payer perspective. Specific AVs included in the model were Antivipmyn, FAV Afrique, Echi-
Tab-G and EchiTab-Plus. We derived inputs from the literature which included: type of
snakes causing bites (carpet viper (Echis species)/non-carpet viper), AV effectiveness
against death, mortality without AV, probability of Early Adverse Reactions (EAR), likelihood
of death from EAR, average age at envenomation in years, anticipated remaining life span
and likelihood of amputation. Costs incurred by the victims include: costs of confirming and
evaluating envenomation, AV acquisition, routine care, AV transportation logistics, hospital
admission and related transportation costs, management of AV EAR compared to the alter-
native of free snakebite care with ineffective or no AV. Incremental Cost Effectiveness
Ratios (ICERs) were assessed as the cost per death averted and the cost per Disability-
Adjusted-Life-Years (DALY) averted. Probabilistic Sensitivity Analyses (PSA) using Monte
Carlo simulations were used to obtain 95% Confidence Intervals of ICERs.
Results
The cost/death averted for the 16 countries of interest ranged from $1,997 in Guinea Bissau
to $6,205 for Liberia and Sierra Leone. The cost/DALY averted ranged from $83 (95% Con-
fidence Interval: $36-$240) for Benin Republic to $281 ($159–457) for Sierra-Leone. In all
cases, the base-case cost/DALY averted estimate fell below the commonly accepted
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004568 March 30, 2016 1 / 16
OPEN ACCESS
Citation: Hamza M, Idris MA, Maiyaki MB, Lamorde
M, Chippaux J-P, Warrell DA, et al. (2016) Cost-
Effectiveness of Antivenoms for Snakebite
Envenoming in 16 Countries in West Africa. PLoS
Negl Trop Dis 10(3): e0004568. doi:10.1371/journal.
pntd.0004568
Editor: H Janaka de Silva, University of Kelaniya,
SRI LANKA
Received: October 19, 2015
Accepted: March 2, 2016
Published: March 30, 2016
Copyright: © 2016 Hamza et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: The authors received no specific funding
for this work.
Competing Interests: At the time of the analysis, AK
was employed by Celgene Corporation, with
ownership of stock in Celgene Corporation.
threshold of one time per capita GDP, suggesting that AV is highly cost-effective for the
treatment of snakebite in all 16 WA countries. The findings were consistent even with varia-
tions of inputs in 1—way sensitivity analyses. In addition, the PSA showed that in the major-
ity of iterations ranging from 97.3% in Liberia to 100% in Cameroun, Guinea Bissau, Mali,
Nigeria and Senegal, our model results yielded an ICER that fell below the threshold of one
time per capita GDP, thus, indicating a high degree of confidence in our results.
Conclusions
Therapy for SBE with AV in countries of WA is highly cost-effective at commonly accepted
thresholds. Broadening access to effective AVs in rural communities in West Africa is a
priority.
Author Summary
Antivenom is the main intervention against snakebite poisoning but is relatively scarce,
unaffordable and the situation has been compounded further by the recent cessation of
production of effective antivenoms and marketing of inappropriate products. Given this
crisis, we assessed the cost effectiveness of providing antivenoms in West Africa by com-
paring costs associated with antivenom treatment against their health benefits in decreas-
ing mortality. In the most comprehensive analyses ever conducted, it was observed the
incremental cost effectiveness ratio of providing antivenom ranged from $1,997 in Guinea
Bissau to $6,205 for Liberia and Sierra-Leone per death averted while cost per Disability
Adjusted Life Year (DALY) averted ranged from $83 for Benin Republic to $281 for
Sierra-Leone. There is probability of 97.3–100% that antivenoms are very cost-effective in
the analyses. These demonstrate antivenom is highly cost-effective and compares favor-
ably to other commonly funded healthcare interventions. Providing and broadening anti-
venom access throughout areas at risk in rural West Africa should be prioritized given the
considerable reduction in deaths and DALYs that could be derived at a relatively small
cost.
Introduction
Snakebite poisoning is a significant cause of death and disability in rural West Africa
[1,2,3,4,5,6,7]. The exact burden of snakebite is difficult to ascertain and is often undere-
ported. A study by Jean-Philippe Chippaux reported an estimate of over 314, 000 envenom-
ations, 7300 mortality and nearly 6000 amputations occurring yearly in sub-Saharan Africa
(SSA) [7]. However, even in West Africa alone, a range of 1504 to 18,654 annual mortality
from snakebite envenoming has been made [8]. This is further compounded by the variabil-
ity in snakebite incidence with estimates of as high as 500 bites per 100,000 persons per year
in parts of northern Nigeria [9].
Vipers (Echis ocellatus, E. leucogaster and E. jogeri) are a major cause of snakebite envenom-
ing throughout the sub-region mainly in Benin republic, Burkina Faso, Cameroun, Chad,
Gambia, Ghana, Mali, Niger, Nigeria, Togo and Senegal [1,2,3,4,5,6,7]. In the sub-region,
envenoming from snakes other than vipers mostly results from African spitting cobras (Naja
nigricollis, N. katiensis), puff-adder (Bitis arietans), mambas (Dendroaspis viridis, D. polylepis),
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burrowing asps or stiletto snakes (Atractaspis species), night adders (Causus maculatus, C.
rhombeatus, C. resimus, C. lichtensteinii) and very rarely boomslang (Dispholidus typus).
Joger’s carpet viper (E. jogeri) is confined to Mali. Romane’s carpet viper (Echis leucogaster)
and Egyptian cobras (Naja haje and N. senegalensis) are causes of snakebite envenoming in the
Sahelian and drier parts of West Africa while the forest cobra (Naja melanoleuca) and the Gab-
oon viper (Bitis gabonica) cause occasional bites in the rain forest and South-eastern parts of
the sub-region [1,5,7].
In West Africa, carpet vipers may account for as many as two thirds of all snakebite enven-
oming although their range is limited to the savannah region [1,9,10,11]. Envenoming from
carpet vipers leads to swelling and tissue damage at the site of bite, local and systematic bleed-
ing, anaemia and shock. Often death results from cerebral haemorrhage, bleeding elsewhere or
haemorrhagic shock [1,10,11]. The bleeding abnormality results from a prothrombin activating
metalloprotease “Ecarin” and a FX activating component, an anticoagulant, platelet activator/
inhibitor and haemorrhagins in the snake’s venom [1,10,11]. Non-clotting blood detected by
the 20minute Whole Blood Clotting Test [20WBCT] virtually confirms carpet viper envenom-
ing in the northern third of Africa (roughly north of the equator) and is utilized to assess ade-
quacy of treatment [1,10,11]. Most non-carpet viper bites lead to local swelling and tissue
damage. The colubrids, boomslangs and twig snake (Thelotornis kirtlandii), are back fanged
snakes that rarely envenom but can cause severe bleeding and acute kidney injury. Neurotoxic
features may result from Naja haje, Naja melanoleuca and Dendroaspis spp bites with deaths
often resulting from respiratory muscle paralysis [12]. The risk of death from snakebites other
than viper envenoming is lower [9,13,14,15,16,17], but cobra spits may lead to blindness and
bites to cancerous ulcers, abortions, scarring, arthrodeses, contractures and psychological
impairment leading to permanent disability and productivity loss following hospitalization and
incapacitation [7,18,19,20,21]. Cessation of bleeding abnormalities and restoration of clotting
following administration of effective antivenom usually occurs promptly in carpet viper enven-
oming. Antivenom is efficacious in decreasing the likelihood of dying and is the main treat-
ment for snakebite envenoming [1,11,22,23]. However, its administration is associated with
early adverse reactions (EAR) which rarely results in fatality.[24,25,26]. Specific interventions
may be required to either prevent EAR with administration of premedication prior to anti-
venom or to treat it once developed following antivenom administration [25,26]. Antivenoms
are formulated as either liquid agents that needs to conveyed and stored at low temperature
with a life span of about three years [27,28] or as freeze dried substances that are more stable
with extended shelf life. Both types of formulations have been produced for the sub-region
[6,27,28]. The average cost per treatment of antivenom was reported as US$124 (range US$55–
$640) although a median price of US$153 was also reported for Sub-Saharan Africa [29,30,31].
The few effective antivenoms in the sub-region generally have been scarce, locally unaffordable
and inaccessible where they are most needed. Partly for these reasons antivenom utilization
has drastically declined to a very small fraction of indicated need. The situation has been com-
pounded further by the recent announcement by Sanofi-Pasteur that production and distribu-
tion of FAV Afrique, currently the most widely distributed and most dependable antivenom in
the sub-region, will be discontinued by 2016. Its loss will exacerbate an already serious public
health crisis and makes the management of snakebite even more challenging [32]. It is there-
fore extremely important within the context of other competing public health priorities to
assess the health economics of antivenoms to guide policy. Before the recent publication of our
work focusing on Nigeria [33], few economic evaluations of preliminary nature had been con-
ducted on antivenoms [34,35]. Here, we evaluated the cost-effectiveness of antivenom utility in
the treatment of snakebite envenomation by computing incremental cost effectiveness ratios
(ICERs) of the cost per death averted and the cost per DALY averted by adapting a previously
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published model for Nigeria to 16 countries in WA. We performed the analysis from health-
care system perspective to provide policy makers with evidence towards broadening access to
antivenoms given their importance in preventing loss of lives and limbs among poor vulnerable
communities in West Africa.
Materials and Methods
Model Overview
A decision analytic model (Fig 1) was adapted to estimate health outcomes and costs associated
with the availability and use of geographically appropriate and effective antivenoms for snake-
bite poisoning in West Africa [33]. Details of the model structure are described elsewhere [33].
Briefly, the model assessed the availability of effective antivenoms relative to no availability in
the decision node. The model differentiated snakebite envenoming by carpet viper and non-
carpet viper and distinction was made on the basis of the 20WBCT in the treatment arm of the
model. Evidence of coagulopathy would lead to the administration of mono-specific antivenom
that neutralizes carpet viper venom only, whereas absence of coagulopathy triggers the admin-
istration of a polyspecific antivenom that neutralizes venoms from several snakes, including
the carpet viper. In the first chance node, the model included EARs associated with antivenom
use, which are more likely to occur with polyspecific rather than the monospecific antivenom
[23,27,28,36,37]. Symptoms of EAR were diverse and death could happen in about 1% of cases
[24,25,26]. Survivors of snakebite may recover completely or remain with significant sequaela
(e.g. amputation) that was considered in the model. Treatment outcomes were converted into
DALYs on the basis of local life expectancy. Tree Age Pro Suite Healthcare 2014 software was
used for analyses.
Model Inputs
Antivenom effectiveness and Early Adverse Reactions (EAR) data. The likelihood of
death from carpet viper and other snakebites among untreated victims was previously reported
at 8.1–15.83% and 5–27.3% respectively [9,10,38,39,40,41,42] although these were varied in
sensitivity analyses. When data on antivenom effectiveness was available for a given country,
it was applied for that country. It ranged from 56.43% to 92% against carpet viper deaths. A
meta-analysis estimate was applied for countries without data (Table 1) [38,39,40]. There
hasn’t been placebo-controlled randomized controlled trials (RCT) ever conducted for anti-
venom assessment and the estimates of effectiveness derived from the meta-analysis that exclu-
sively only included observational studies from Chad, Ghana and Nigeria [10,22,37,38,39] were
applied in the model. Results from the meta-analysis suggested that an effective antivenom has
a 75% (95% confidence interval: 55–86%) effectiveness in averting mortality from carpet viper
bites [22]. Since the meta-analysis included studies wherein polyspecific antivenoms were used,
these estimates of effectiveness were applied against non-carpet viper deaths except in Benin
and Guinea-Conakry, where country-level effectiveness data exists for Antivipmyn antivenom
against non-carpet viper (elapid) deaths, reported at 43.6% (0–80.5%) (Table 1) [42]. However,
in a scenario analysis antivenoms were assumed to be ineffective (0%) against non-carpet viper
envenoming. Estimates of EAR for the corresponding antivenoms were Antivipmyn 3.3% and
FAV Afrique 4.3% as obtained in observational studies while it was EchiTab-G 19% and Echi-
Tab-Plus 26% [23,36,37]. For countries where none of the antivenoms have been in use, the
EAR risk median estimate of 4.3% was used in the model [36]. The EAR estimates were varied
from 0% to 30% in sensitivity analyses. The risk for disability (limb amputation) among survi-
vors was approximated to 3% from studies in sub-Saharan Africa and the tropics [7,43,44]. In
base-case analysis antivenom administration had no effect on amputation, however,
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Fig 1. Decision tree model for managing snakebite envenoming with or without FAV Afrique antivenom in Cameroun (each of the 16 countries has
a similar model with its data input).Model parameter definitions: c20WBCTest = cost of 20 minutes Whole Blood Clotting Test on 10 occassions over 7
days at diagnoses and monitoring; cAdvReaction = Cost of managing early adverse reactions; cAntivenom = Cost of Antivenom; cFeed_Transp = Cost of
transporation and stay in Hospital for 7days; cRefrg_Transp = Cost of shipping and refrigeration; cNoAntivenom = Cost of management without effective
antivenoms either traditional/herbal care or other alternatives; cSupp_care = Cost of supportive care. All costs are in US$. antivenomeff = Effectiveness of
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effectiveness was applied in sensitivity analyses. The mean ages of snakebite envenomed vic-
tims were reported for Chad 25.2 years, Niger 29 years, Nigeria 26 years and Mali 28 years
[38,39,41,45,46]. So, since snakebite envenoming occurs among persons with average age in
the 25–29 year age group, we determined the remaining local life expectancies in this age group
for the 16 countries ranged from 37 years in Sierra-Leone to 45 years in Ghana and Senegal
(Table 1) [47]. The base-case analysis on disability was restricted to extremity amputation
although blindness from venom-ophthalmia and Post Traumatic Stress Disorder (PTSD)
from encountering snake with respective disability weights of 0.552 and 0.105 [48] were also
explored in scenario analyses. An annual discount rate of 3% was applied on the health out-
comes (mortality and amputation) and the associated amputation-related disability weight
used was 0.102 [48]. The model was adapted to 3 types of antivenoms used in WA: Antivipmyn
in Benin and Guinea Conakry; EchiTab-G and EchiTab-Plus in Burkina Faso and Nigeria;
FAV Afrique in Cameroun, Chad, Ghana and Mali. For the remaining 8 countries without evi-
dence of effectiveness data for a particular antivenom, the meta-analytic estimates were used
[22]. Where other required data item was unavailable, data from adjacent or neighboring coun-
tries were used to input a model with mixed data sources. These parameters for the respective
models were obtained in the literature and imputed to the antivenom-defined models and was
run for each of the 16 countries.
Cost data. The cost of the full antivenom treatment regimen was modeled as US$153
[29,30,31]. The cost of care, ten 20WBCT measurements in 7 days, transportation to-and-from
hospital and feeding for 7 days, shipping and freezing of antivenom, management of EAR, sup-
portive care (such as pain relief, blood transfusion, medications, fluid replacement and wound
management) were obtained from series of envenomed patients admitted to Kaltungo General
Hospital in Nigeria Table 2 [33]. All costs were expressed in US$. Given snakebite is a short
term condition and costs occur during a brief period of time (2 to 10 days), costs were not dis-
counted to adjust for time elapsed between expenditure and outcome during Incremental Cost
Effectiveness Ratio (ICER) calculations [49,50]. As a conservative analysis the alternative of no
antivenom therapy carried a cost of zero as no treatment, care, test and EAR management was
provided. However, in a scenario analysis cost of $65.63 was added/incurred for the alternative
of no antivenom therapy, comprising of supportive care $18.75, feeding and transportation
$43.75, and for 20WBCT $3.125. The ICER was computed by dividing total cost by the differ-
ence in DALYs (e.g., cost/DALY averted) [49,50].
Sensitivity analysis. One-way sensitivity analysis was performed for select input variables
to test robustness and determine the most important variables influencing cost-effectiveness
of an antivenom programme. Each base-case model input was varied independently according
to the upper and lower limits obtained from literature and according to low and high value
scenarios.
In addition, Probablistic Sensitivity Analyses (PSA) were performed using Monte Carlo sim-
ulation by running 10,000 iterations of the model while randomly selecting the values for 16
key model inputs from a probability distribution that was defined for each of the parameters
(Table 2). This process enabled us to estimate the 95% confidence interval around the base case
ICER estimates for each of the 16 countries included in the analysis, and it also allowed us to
estimate the probability that antivenom therapy is cost-effective by calculating the proportion
antivenom to prevent death; pEARmono = probability of early adverse reactionswith monospecific antivenom; pEARpoly = probability of early adverse
reactionswith polyspecific antivenom; pEARmort = probability of dying following effective antivenom and early adverse reactions; pCVmort = probability of
dying following carpet viper envenoming; pNCVmort = probability of dying following non-carpet viper envenoming; pCV = proportion of envenoming due to
carpet viper; pDisabl = probability of disability; dw = disability weighting of consequences of snakebite envenoming; x = effect of adrenaline premedication
reduction of risk of early adverse reactions.
doi:10.1371/journal.pntd.0004568.g001
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Table 1. Data estimates used in the model by country.
(a) Mean age at
bite
(+remaining
life expectancy
[2012]), years
(b) Proportion
of envenoming
due to CV or
vipers (%)
(c)
Untreated
Mortality
(CV; Non-
CV)
(d)
Mortality
post AV
(CV; Non-
CV)
AV effectiveness
against mortality
(e) = [1-RR] or
alternatively = (c-
d)/c (for CV; Non-
CV)
Risk of Early
Adverse
Reactions
with CV
(mono) and
NCV(poly[(%)
Comments References
Model 1: Antivipmyn Antivenom
Benin
Republic
25–29 (44) 85% 15%; 9/33
(27.3%)
3.11%; 4/
26(15.4%)
79.3%; (NA)
43.6% (0–80.5%)
3.3% Used NCV
data from
Guinea
Fayomi et al 2002
[4]; Chippaux et al
2007 [6]; Balde
et al 2012 [37];
Balde et al 2013
[42];
Guinea-
Conakry
25–29 (43) 83% 15%; 9/33
(27.3%)
3.11%; 4/
26(15.4%)
79.3%; (NA)
43.6% (0–80.5%)
3.3% Used CV
data from
Benin
Fayomi et al 2002
[4]; Chippaux et al
2007 [6]; Balde
et al 2012 [37];
Balde et al 2013
[42]; Adehossi
et al 2011 [45];
Model 2: EchiTab-G and EchiTab-Plus Antivenom
Nigeria 26 (41) 66% 19/120
(15.83%);
5%
78/6137
(1.27%)
92% (87–95%) ET-19%;
ETPlus-26%
Warrell et al 1977
[10]; Abubakar
et al 2010[23];
Habib &
Abubakar 2011
[38]; Pugh et al
1980 [13]
Burkina
Faso
25–29 (43) 85% 12.1%; 5% NA 92% (87–95%) ET-19%;
ETPlus-26%
Used AV
effect from
Nigeria;
Ghana
mortality
Warrell et al 1977
[10]; Abubakar
et al 2010[23];
Habib &
Abubakar 2011
[38]; Visser et al
2008 [40]; Pugh
et al 1980 [13]
Model 3: FAV Afrique Antivenom
Cameroon 25–29 (41) 85% 15/98
(15.3%)
NA 85.2%(56.1–95%); 4.3% Used (c) &
(e) from
Chad/Ghana
Chippaux et al
1999 [36];
Bregani et al
2006 [39]; Visser
et al 2008 [40];
Chad 25.2 (38) 85% 15/98
(15.3%)
4/60
(6.67%)
56.43% (0–85.2%); 4.3% Chippaux et al
1999 [36];
Bregani et al
2006 [39];
Ghana 25–29 (45) 85% 8/66
(12.1%); -
5/278
(1.8%)
85.2%(56.1–95%); 4.3% Chippaux et al
1999 [36]; Visser
et al 2008 [40];
Mali 28 (43) 85% 8.1%; 5% 1.5% 81.48% (NA) 4.3% Chippaux et al
1999 [36]; Drame
et al 2012 [41]
Other/Multiple Antivenoms
Cote
d’Ivoire
25–29 (39) 83% 12.1%;- 75%(55–86%)- 4.3% AV efﬁcacy
from meta-
analysis
Habib & Warrell
2013 [22];
Chippaux et al
1999 [36]; Visser
et al 2008 [40];
(Continued)
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of 10,000 iterations that resulted in ICERs that fell below commonly accepted cost-effectiveness
thresholds of one time per capita Gross Domestic Product (GDP) for each of the 16 countries
[51,52].
The study reporting was done consistent to standard guidelines for cost effectiveness analy-
ses and the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) state-
ment [49,50,52,53,54].
Results
The cost/death averted for the 16 countries of interest varied. It was as low as $1,997 in Guinea
Bissau to as high as $6,205 in Liberia and Sierra Leone. The cost/DALY averted ranged from a
low of $83 (95% Confidence Interval: $36-$240) for Benin Republic to a high of $281 ($159–
457) for Sierra-Leone. In all cases, the base-case cost/DALY averted estimate fell below the
Table 1. (Continued)
(a) Mean age at
bite
(+remaining
life expectancy
[2012]), years
(b) Proportion
of envenoming
due to CV or
vipers (%)
(c)
Untreated
Mortality
(CV; Non-
CV)
(d)
Mortality
post AV
(CV; Non-
CV)
AV effectiveness
against mortality
(e) = [1-RR] or
alternatively = (c-
d)/c (for CV; Non-
CV)
Risk of Early
Adverse
Reactions
with CV
(mono) and
NCV(poly[(%)
Comments References
Gambia 25–29 (44) 40% 14.3% 75%(55–86%) 4.3% Enwere et al 2000
[3]; Habib &
Warrell 2013 [22];
Chippaux et al
1999 [36];
Guinea-
Bissau
25–29 (41) 40% 15%; 27.3% 75%(55–86%);
43.6% (0–80.5%)
4.3% Habib & Warrell
2013 [22]; Balde
et al 2013 [42];
Adehossi et al
2011 [45];
Liberia 25–29 (44) 0% (*1%) 0%
(*15%);5%
75%(55–86%) 4.3% Pugh et al 1980
[13] Habib &
Warrell 2013 [22];
Niger 29 (44) 85% 15%; 5% 75%(55–86%) 4.3% Habib & Warrell
2013 [22];
Chippaux et al
1999 [36]; Fayomi
et al 2002 [4];
Adehossi et al
2011 [45];
Senegal 25–29 (45) 40% 15%;5% 75%(55–86%) 4.3% Trape et al 2002
[5];Habib &
Warrell 2013 [22];
Chippaux et al
1999 [36];
Adehossi et al
2011 [45];
Sierra-
Leone
25–29 (37) 0% (*1%) 0%
(*15%);5%
75%(55–86%) 4.3% Pugh et al 1980
[13] Habib &
Warrell 2013 [22];
Togo 25–29 (43) 85% 12.1%; 5% 75%(55–86%)— 4.3% Habib & Warrell
2013 [22]; Visser
et al 2008 [40];
CV—carpet viper; RR—Relative Risk
doi:10.1371/journal.pntd.0004568.t001
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commonly accepted threshold of one time per capita GDP, suggesting that AV is highly cost-
effective for the treatment of snakebite in all 16 WA countries [51,52].
The findings from the analyses were also consistent to variations of inputs in 1-way sensitiv-
ity and scenario analyses as depicted (Table 3 and Fig 2). The individual countries’model
results were most sensitive to effectiveness of antivenom in decreasing mortality, natural (unat-
tended) mortality, costs of antivenoms and types of snake causing envenoming (Fig 2). Results
were not sensitive to antivenom associated EAR or the cost of managing it. Varying the cost
of antivenom from $125 to two times for victims who may require two doses, i.e. $306, still
yielded ICER estimates that remain cost-effective. The ICERs rose when the frequency of
snakebite envenomation due to saw-scaled viper was reduced to 0% except in Benin and
Guinea Conakry where Antivipmyn antivenom is used and is effective even against elapids
(Table 3) [42].
Moreover, the ICER ranged from $97.26 in Benin to high levels of $13,964.26 in Liberia and
$15,278.99 in Sierra Leone even in the worst case scenario where (poly-specific) antivenoms
have nil effectiveness (0%) against bites from snakes other than carpet viper. These estimates
fall outside the cost-effectiveness thresholds in Liberia and Sierra Leone largely because non-
carpet viper accounts for 99% of SBE. Applying a modest reduction of 40% on the probability
of EAR with the use of adrenaline premedication [25,26,33] gave a cost per DALY averted
slightly lower than base-case ICERs. Similarly, the ICERs were only very slightly altered even
when more serious or more frequent disabilities were substituted in the model. This was dem-
onstrated with venom-induced-blindness (0.01%) or Post-Traumatic-Stress-Disorder (20%)
with disability-weights of 0.552 and 0.105 respectively [18,21,48].
Furthermore, our PSA confirms the model findings remain consistent to concurrent varia-
tion of all model inputs, as the ICERs with their respective 95% confidence limits are far less
than the cost-effectiveness thresholds (Table 3). It showed that in majority of simulations
(97.3% in Liberia to 100% in Cameroun, Guinea Bissau, Mali, Nigeria and Senegal (Fig 3)) our
Table 2. General assumptions used in Monte Carlo simulations.
Assumption Base Case Value (BCV) Range of BCVs Distribution Reference
Proportion of envenoming due to CV/ Non-Elapids (%) Varies by country 1–85% Beta 1,5,6,7,36
Mortality due to untreated CV envenoming (%) Varies by country 8.1–15.83% Beta 3,4,10,39,40,41,45
Mortality due to untreated Non-CV/Elapid envenoming (%) Varies by country 5–27.3% Beta 13,14,42
AV effectiveness against CV mortality (%) Varies by country 56.43–92% Beta 4,6,10,22,38,39,40,41
AV effectiveness against Non-CV/Elapid mortality (%) Varies by country 43.6–92% Beta 10,38,42
Risk of AV EAR for CV envenoming (%) Varies by country 3.3–19% Beta 23,36,37
Risk of AV EAR for Non-CV envenoming (%) Varies by country 3.3–26% Beta 23,36,37
Risk of AV EAR mortality (%) 1% Same for each country Beta 24
Risk of amputation following envenoming (%) 3% Same for each country Beta 7,43,44
Disability weight for amputation 0.102 Same for each country Beta 48
Cost of antivenom (US$) $153 Same for each country Normal 29,30,31
Cost of 20min Whole Blood Clotting Test $3.125 Same for each country Normal 33
Cost of managing Early Adverse Reactions $1.875 Same for each country Normal 33
Cost of supportive care $18.75 Same for each country Normal 33
Cost of feeding and transportation $43.75 Same for each country Normal 33
Cost of refrigeration and transportation $18.75 Same for each country Normal 33
Cost of no antivenom (US$) $0 Same for each country Not varied Our assumption
DALYs averted per death averted (3% discounted) Varies by country 22.17–24.52 Not varied Our calculations
DALYs averted per amputation averted (3% discounted) Varies by country 2.26–2.50 Not varied Our calculations
doi:10.1371/journal.pntd.0004568.t002
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Table 3. Results frommodel outputs by country and scenarios.
Country and
GDP/Capita
($) [49]
Increm Cost
Effect Ratio
[ICER]/DALY
($) (95%
Conf.
Interval)
Cost/
Death
Averted
($)
Probability
Antivenom is
cost-effective
(%)
ICER if
Antivenom
Cost = $125
ICER if
Antivenom
Cost = $306
ICER if
proportion of
Carpet
Viper = 0% ($)
ICER if Av
Effect for Non
Carpet
Viper = 0% ($)
ICER if the ‘No
Antivenom’ arm
paid for Basic
costs of $65.63*
Benin (751) 82.63 (36.41–
240.09)
1997.91 99.99 72.87 135.96 81.75 97.26 59.75
B/Faso (652) 99.44 (40.39–
377.40)
2384.81 99.61 87.98 164.05 226.53 107.18 71.94
Cameroun
(1220)
86.97 (38.47–
240.43)
2030.05 100.00 76.70 143.11 238.39 92.01 62.89
Chad (1035) 136.94
(51.33–
704.75)
3070.80 99.13 120.77 225.34 376.61 144.89 99.03
Cote d’Ivoire
(1366)
128.24
(51.20–
461.64)
2916.02 99.97 113.09 211.04 278.37 139.16 92.73
Gambia
(509)
150.08
(72.18–
305.49)
3628.88 99.99 132.25 247.47 261.77 229.59 108.30
Ghana
(1646)
103.61
(42.04–
372.87)
2532.73 99.99 91.38 170.50 227.63 111.21 74.93
Guinea
Bissau (576)
87.09 (44.96–
171.55)
2032.72 100.00 76.75 143.60 84.76 226.64 62.85
Guinea
Conakry
(493)
83.54 (36.59–
236.35)
1997.41 99.98 73.67 137.49 82.68 100.72 60.40
Liberia (414) 256.61
(147.67–
417.68)
6204.95 97.28 226.00 423.92 261.77 13,964.26 184.85
Mali (696) 160.48
(82.21–
306.83)
3836.74 100.00 141.52 264.06 243.47 178.09 116.04
Niger (385) 97.23 (39.84–
328.02)
2351.06 98.64 85.75 159.99 261.77 102.98 70.31
Nigeria
(2742)
92.56 (40.27–
242.63)
2160.33 100.00 81.61 152.35 232.04 107.96 66.91
Senegal
(1023)
143.81
(67.34–
317.76)
3515.25 100.00 126.73 237.14 258.95 216.41 103.78
Sierra Leone
(590)
280.77
(158.51–
456.68)
6204.95 99.86 247.27 463.83 286.42 15,278.99 202.25
Togo (589) 120.42
(47.62–
455.04)
2878.98 98.86 106.19 198.14 264.75 129.25 87.08
*Scenario of Basic costs in the No antivenom arm = Cost of supportive care ($18.75) + Cost of feeding and transportation ($43.75) + Cost of 20min Whole
Blood Clotting Test ($3.125) = $65.63
AV—antivenom; ICER—Incremental Cost Effectiveness Ratio;
doi:10.1371/journal.pntd.0004568.t003
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model results yielded an ICER that fell below the threshold of one time per capita GDP, thus,
indicating a high degree of confidence in our results [51,52].
Discussion
Economic modeling is very useful in determining the best ways to utilize resources to optimally
manage medical conditions where there are competing priorities and limited resources [49].
This is the first extensive assessment of the cost-effectiveness of expanding antivenom access in
the 16 countries in West Africa. We find that the cost/death averted for the 16 countries of
interest ranged from $1,997 in Guinea Bissau to $6,205 for Liberia and Sierra Leone. The cost/
DALY averted ranged from $83 (95% Confidence Interval: $36-$240) for Benin Republic to
$281 ($159–457) for Sierra-Leone. The ICER point estimate is<$100/DALY averted in 7 coun-
tries, $100-$200/DALY averted in 7 countries and<$300/DALY averted in 2 countries. The
results show that snakebite antivenoms are highly cost-effective in West Africa, as our findings
are far less than the one time per capita GDP threshold [51,52]. While it will be worthwhile to
repeat the analysis for similar geographic and socioeconomic settings, most of the model inputs
such as the antivenom efficacy and cost would largely be similar across many African countries
Fig 2. Tornado diagrams assessing the impact of changes in envenoming/antivenom and cost parameters on the incremental cost-effectiveness
ratio (ICER) per DALY for antivenom use in Guinea Bissau (L) and Senegal (R). Diagram parameter definitions: c20WBCTest = cost of 20 minutes
Whole Blood Clotting Test on 10 occassions over 7 days at diagnoses and monitoring; cAntivenom = Cost of Antivenom; cFeed_Transp = Cost of
transporation and stay in Hospital for 7days; cRefrg_Transp = Cost of shipping and refrigeration; cNoAntivenom = Cost of management without effective
antivenoms either traditional/herbal care or other alternatives; cSupp_care = Cost of supportive care. All costs are in US$. Antivenomeff = Effectiveness of
antivenom to prevent death; pEARmono = probability of early adverse reactions with monospecific antivenom; pEARpoly = probability of early adverse
reactionswith polyspecific antivenom; pEARmort = probability of dying following effective antivenom and early adverse reactions; pCVmort = probability of
dying following carpet viper envenoming; pNCVmort = probability of dying following non-carpet viper envenoming; pCV = proportion of envenoming due to
carpet viper; pDisabl = probability of disability.
doi:10.1371/journal.pntd.0004568.g002
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with similar GDPs where snakebite envenoming occurs. An exception may be the prevalence
of carpet viper (Echis ocellatus) envenoming, a snake that is confined to West Africa extending
eastwards only as far as Chad and Central Africa Republic. However, even in areas without car-
pet viper bites (0%) our results demonstrate that antivenoms remain highly cost-effective.
The combination of effective and relatively inexpensive antivenoms and the utilization of a
cheap, dependable and simple point-of-care test have been instrumental to our results. Anti-
venom effectiveness is loosely inversely related to the ICER per DALY saved (Fig 2) [33]. With
discontinuation of production of geographically appropriate effective antivenoms and market-
ing of inappropriate ineffective products the cost per DALY saved will substantially soar
[32,39,40]. The 20WBCT is discriminatory and will be useful following envenoming from
other snakes in the rest of Africa that result in coagulopathy e.g., other species of carpet viper
(Echis leucogaster, Echis pyramidum, Echis jogeri, Echis coloratus) and boomslang. In the
Fig 3. Monte Carlo Simulation showing the probability antivenom is cost-effective in majority of iterations (out of 10,000) for 4 countries with
respective Willingness To Pay (GDP/capita) and probabilities: top panel Chad (WTP $1035; prob-99.13%) [L] and Liberia (WTP $414; prob-97.28%)
[R] and bottom panel Niger (WTP $385; prob-98.64%) [L] and Togo (WTP $589; prob-98.86%) [R].
doi:10.1371/journal.pntd.0004568.g003
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context of differing circumstances where multiple types of snakes with varying manifestations
of envenoming or lack of reliable cheap differentiating test, antivenoms may not be as cost-
effective. Nevertheless, where patients come along with the dead snakes, decision on antivenom
choice is feasible [23] and in such cases the differentiating test becomes not so useful. In the
face of competing health needs and constrained-resources, it would be helpful to contextualize
our findings in the light of other healthcare initiatives. The cost-effectiveness of Human Immu-
nodeficiency Virus treatment used in similar resource-constrained settings as first-line, sec-
ond-line or for protecting negative partners among discordant partners ranged from US$530
to US$1037 per year of life gained [33,55,56,57]. However, these estimates are still higher than
the highest ICERs obtained for two countries in this analysis, i.e., Liberia and Sierra-Leone
with $257/DALY averted and $281/DALY averted respectively. The antivenom cost effective-
ness is comparable to what obtains in other healthcare programmes. For example, the cost/
DALY averted obtained in this study ranged from $100 to $200 for 7 countries (see Table 3)
and is comparable to the cost effectiveness of rotavirus vaccines in other developing countries
in Africa and Asia [33,58,59]. Similarly, the cost/DALY averted in the remaining 7 countries
was<$100/DALY averted and is similar to what obtains for preventing Human Papilloma
Virus and pneumococcal infections with vaccines in West Africa [33,60,61].
We estimated a cost/DALY averted ranging from $73 in Benin to $247 in Sierra Leone if the
cost input of antivenom is reduced to $125 per dose as obtained in Mali [30]. Doubling the cost
of antivenom for patients requiring more than a dose still yielded ICERs that remain cost effec-
tive ranging from $136/DALY averted in Benin to $464/DALY averted in Sierra Leone.
In 8 of the 16 countries with neither indigenous antivenom effectiveness data nor data from
adjacent countries, we used efficacy derived from a meta-analysis with data inputs from other
countries in the sub-region [22, 38].
The study has a number of limitations. First, the effectiveness of antivenom was derived
from observational studies rather than RCTs. Definitive placebo controlled trials of anti-
venom are considered unethical and RCTs are unlikely to be conducted in the absence of a
suitable comparator to antivenom. However, to reduce bias, improve data quality and validity
of estimates, three investigators independently searched both English and French literature
and extracted data using a checklist for consistency. Secondly, we applied the estimated pro-
tection conferred by antivenoms against carpet viper envenoming to the antivenoms used for
other than carpet viper envenoming (except in Benin and Guinea Conakry with specific esti-
mates), though this assumption was subsequently dropped in a scenario analysis where anti-
venoms were assumed to be ineffective (0%) against non-carpet viper envenoming. Thirdly,
the analysis mainly considered amputation as the major disability to the exclusion of other
anecdotal complications [7, 20, 43, 44]. Fourthly, in our model, antivenoms only conferred
protection against death—being a more objective and valid outcome. Fifthly, other benefits
of antivenom (e.g. speedier recovery) were not included in the model. Sixth, we used separate
EAR risk inputs for EchiTab-G and EchiTab-Plus respectively [23] but could not discern
their respective efficacy against mortality so the combined estimate of the two was used in
Burkina Faso and Nigeria. Lastly, we did not include the costs incurred for logistics in con-
veying and preserving antivenoms as we assumed facilities for existing health programmes
will be utilized.
Conclusion
The findings from the cost effectiveness analysis demonstrate that providing and broadening
antivenom access throughout areas at risk in rural West Africa should be prioritized given the
considerable reduction in deaths and disabilities that could be derived at a relatively small cost.
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